This drug is currently in Phase 2 clinical trials
They can evaluate your hormone levels and health status
pmid:31002893 18
It is not designed for manual adjustments or do-it-yourself modifications
Results: SG significantly reduced in scores for steatosis (0.87 0.69 to 0.48 0.73, P = 0.007), hepatocellular ballooning (0.52 0.59 to 0.13 0.46, P = 0.003), lobular inflammation (0.74 0.75 to 0.35 071, P = 0.007), fibrosis (1.04 1.22 to 0.57 0.99, P = 0.016), and NAFLD activity score (2.39 2.17 to 0.96 1.77, P = 0.001), together with AST 24.0 (21.0 -35.0) to 16.0 (14.0 - 27.0) IU/L, P = 0.003, ALT 46.0 (27.0 - 61.0) to 17.0 (11.0 - 25.0) IU/L, P = 0.001, and GGT (36.3 33.0 to 22.6 20.6 IU/L, P = 0.013), fasting plasma glucose 92.0 (85.0 - 122.0) to 85.0 (80.0 - 96.0) mg/dL, P = 0.003, hemoglobin A1c 6.0 (5.6 - 6.9) to 5.4 (5.2 - 6.4)%, P = 0.018, body weight (99.0 13.5 to 75.6 16.1 kg, P 36 was defined as MAFLD
It includes measures of brain speed, brain wave power and reaction time
